Mucinex® ER 600 mg Bi-layer Tablet Versus Guaifenesin Immediate Release (IR) 200 mg q4h
Status:
Completed
Trial end date:
2013-08-09
Target enrollment:
Participant gender:
Summary
Demonstrate bioequivalence of guaifenesin in Mucinex® extended release (ER) 600 mg tablet in
normal healthy volunteers compared to the immediate release guaifenesin 200 mg tablet
reference product marketed
Phase:
Phase 1
Details
Lead Sponsor:
Reckitt Benckiser Inc.
Treatments:
Chlorpheniramine, phenylpropanolamine drug combination Guaifenesin Phenylpropanolamine